Movements in molecular diagnostics

Several recent billion-dollar merger and acquisition deals have expanded the range of services provided by leading molecular diagnostics companies.

By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.

The precision medicine services company Oncolines B.V. is accelerating cancer drug development by identifying drug response biomarkers in over 200 genetically characterized cancer cell lines.

Heligenics is using its first-in-class platform for whole-gene drug-resistance profiling to progress precision prescriptions.